» Articles » PMID: 28011332

Cardiac Complications in Cancer Treatment - A Review

Overview
Date 2016 Dec 25
PMID 28011332
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiac dysfunction is often associated with effective cancer treatment. A number of targeted therapies against cancer have been observed to cause cardiac dysfunction. In some instances, a patient may outlive his or her cancer but die due to heart failure. Recent research has been focused on the development of new avenues and technological advancements to monitor clinical cardiotoxicity and cardiac dysfunction due to anticancer treatment. These newer treatment options are also increasingly effective and are focused more on post-cancer life. The present review article expands the current view of cardiac complications involved in cancer treatment along with the recent developments in the area.

Citing Articles

Evaluating the risk of comorbidity onset in elderly patients after a cancer diagnosis.

Islam M, Saif M, Alam N, Pepper S, Ratnayake I, Mudaranthakam D BMC Public Health. 2025; 25(1):640.

PMID: 39962420 PMC: 11834647. DOI: 10.1186/s12889-025-21784-7.


Evaluating the Risk of Comorbidity Onset in Elderly Patients After a Cancer Diagnosis.

Islam M, Islam T, Saif S, Saif M, Alam N, Pepper S Res Sq. 2025; .

PMID: 39764109 PMC: 11702800. DOI: 10.21203/rs.3.rs-5189676/v1.


A prospective randomized controlled trial to determine the safety and efficacy of extracorporeal shock waves therapy for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.

Song S, Woo J, Kim H, Lee J, Lim W, Moon B Front Cardiovasc Med. 2024; 11:1324203.

PMID: 38385137 PMC: 10879594. DOI: 10.3389/fcvm.2024.1324203.


Extract Ameliorates Doxorubicin-Induced Cardiotoxicity by Decreasing Apoptosis.

Ono M, Sunagawa Y, Mochizuki S, Katagiri T, Takai H, Iwashimizu S Cancers (Basel). 2022; 14(3).

PMID: 35158951 PMC: 8833354. DOI: 10.3390/cancers14030683.


Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Protect Cardiomyocytes from Doxorubicin-Induced Cardiomyopathy by Upregulating Survivin Expression via the miR-199a-3p-Akt-Sp1/p53 Signaling Pathway.

Lee J, Chung J, Byun Y, Kim K, An S, Kwon K Int J Mol Sci. 2021; 22(13).

PMID: 34281156 PMC: 8267634. DOI: 10.3390/ijms22137102.